A groundbreaking study led by researchers from the University of Cambridge, Addenbrooke’s Hospital, and Queen Mary University of London heralds a transformative shift in the surveillance of Barrett’s oesophagus—a known precursor to oesophageal cancer. Traditionally, monitoring this condition has relied on invasive endoscopies, procedures that are often uncomfortable, resource-intensive, and dependent on operator skill. However, the newly developed capsule sponge test promises a minimally invasive, efficient, and potentially more reliable alternative, capable of replacing endoscopy for up to half of patients diagnosed with Barrett’s oesophagus.
Endoscopy, the current gold standard for surveillance, requires passing a flexible camera down the throat into the stomach to visually inspect the oesophageal lining for precancerous changes. This process, while effective, places heavy demands on healthcare systems, especially within the NHS, where long waiting times and limited resources can delay crucial diagnosis and intervention. Furthermore, endoscopies require sedation or anesthesia, often necessitating additional support and recovery time, which adds to patient discomfort and healthcare burdens alike.
Barrett’s oesophagus arises when cells lining the oesophagus undergo metaplastic transformation—shifting from normal squamous epithelium to a columnar cell type more commonly found in the intestines. This cellular alteration, triggered by chronic acid exposure such as in gastroesophageal reflux disease (GERD), may progress to dysplasia and eventually to oesophageal adenocarcinoma, a particularly lethal form of cancer. Early detection and monitoring of dysplasia stages—categorized as low-grade or high-grade—are critical, as they inform treatment strategies that can prevent progression to invasive cancer. Despite this, the current reliance on repeated endoscopies is far from ideal due to its invasiveness and variability in detection accuracy.
.adsslot_m5yoA6Bbvs{ width:728px !important; height:90px !important; }
@media (max-width:1199px) { .adsslot_m5yoA6Bbvs{ width:468px !important; height:60px !important; } }
@media (max-width:767px) { .adsslot_m5yoA6Bbvs{ width:320px !important; height:50px !important; } }
ADVERTISEMENT
The capsule sponge test innovatively addresses these challenges by combining ease of administration with molecular precision. Patients swallow a gelatin capsule attached to a string, which dissolves upon reaching the stomach to release a porous medical-grade sponge. When retracted through the oesophagus, the sponge collects epithelial cells by gently scraping the mucosal surface. The retrieved cellular sample is then subjected to laboratory staining and analysis for key biomarkers, specifically, abnormalities in the tumor suppressor protein p53 and cytological atypia.
These biomarkers serve as “red flags” indicating the presence of precancerous changes. Alterations in p53 function are critical in tumorigenesis, given p53’s role in DNA repair and apoptosis. Identifying p53 mutations or irregular expression patterns via this novel method provides an objective measure of neoplastic risk. Similarly, the identification of atypical cells, which display irregular shapes, sizes, or staining patterns under microscopy, further refines risk stratification, guiding clinicians in tailoring patient surveillance protocols.
In an extensive UK-wide prospective study encompassing 910 patients across 13 hospitals, the research team meticulously evaluated the real-world applicability of this capsule sponge technique. Each participant, already diagnosed with Barrett’s oesophagus, underwent the capsule sponge procedure alongside their routine endoscopy, enabling direct comparison of diagnostic outcomes. The study’s striking findings revealed that 15% of patients were classified as high risk, based on presence of p53 abnormalities and/or cytological atypia, with over a third (38%) demonstrating precancerous pathology upon confirmatory endoscopy. Most notably, among those exhibiting both risk markers, an overwhelming 85% were found at a precancerous stage.
Patients without these biomarkers but meeting certain demographic and clinical criteria—such as longer Barrett’s segment length, age, and sex—were stratified into a moderate risk category and recommended to continue with endoscopic surveillance. Crucially, more than half (54%) of the cohort fell into the low-risk category, lacking both biomarkers and additional risk factors. Endoscopy validated this stratification: only two out of 495 low-risk patients (0.4%) harbored high-grade dysplasia warranting closer follow-up, and no invasive cancers were detected in this group.
The implications of these results are profound. The capsule sponge test not only reliably identifies patients requiring urgent intervention but also enables a safe reduction in the frequency of invasive endoscopies for those at minimal risk. This holds tremendous promise for alleviating the healthcare burden, improving patient experience, and optimizing resource allocation within constrained clinical settings.
Professor Rebecca Fitzgerald, a leading gastroenterologist and one of the study’s principal investigators, emphasized the significance of these developments, highlighting the need for surveillance tools that minimize patient discomfort yet maximize diagnostic accuracy. “Our findings demonstrate a powerful alternative to the traditional endoscopy, enabling broader access to surveillance while maintaining clinical safety. The capsule sponge test is less operator-dependent and could revolutionize how we monitor Barrett’s oesophagus,” she said.
In turn, Dr. W. Keith Tan, the study’s first author and a gastroenterology registrar, underscored the practical benefits of deploying the capsule sponge in community healthcare settings. The procedure can be administered quickly by trained nursing staff without the elaborate setup required for endoscopy, eliminating the need for sedation and reducing patient downtime. Patients can resume daily activities immediately after the test, a feature warmly welcomed by participants like Duncan Cook, a plumbing engineer who has undergone regular endoscopies for nearly two decades. Speaking from personal experience, Cook described the capsule test as a “much better” alternative, appreciating its convenience and the absence of sedation-related side effects.
These promising outcomes are set against the backdrop of stagnating survival rates for oesophageal cancer, which sadly remain under 20% five years post-diagnosis despite advances in treatment. The incidence of oesophageal adenocarcinoma has surged over recent decades, amplifying the urgency for improved early detection and surveillance methods. The capsule sponge test’s ability to stratify patients effectively and facilitate timely, targeted intervention could be a critical factor in reversing this troubling trend.
Beyond the immediate clinical implications, the research also dovetails with ongoing efforts to enhance translational cancer research infrastructure. The upcoming Cambridge Cancer Research Hospital aims to co-locate clinical expertise and scientific innovation, creating an ecosystem where novel diagnostics like the capsule sponge can be refined, tested, and rapidly implemented within the NHS framework. The integration of such technologies into routine practice holds the prospect of significantly improving patient outcomes and healthcare efficiency on a national scale.
Supported by prominent funding bodies including Cancer Research UK, Innovate UK, the Medical Research Council, and the NIHR Cambridge Biomedical Research Centre, this landmark study exemplifies the synergy of multidisciplinary collaboration in confronting one of the most challenging cancers. The results were published in the June 2025 issue of The Lancet, signaling a pivotal step in cancer surveillance innovation with wide-reaching implications.
As these findings permeate the medical community, the capsule sponge test is poised to become a cornerstone in personalized, risk-adapted care for Barrett’s oesophagus patients worldwide. Its combination of molecular precision, patient acceptability, and health system compatibility heralds a new era in the early detection and prevention of oesophageal cancer.
Subject of Research: People
Article Title: Biomarker risk stratification with capsule sponge in the surveillance of Barrett’s oesophagus: Prospective evaluation of UK real-world implementation
News Publication Date: 23-Jun-2025
Web References: http://dx.doi.org/10.1016/S0140-6736(25)01021-9
References: Tan, WK et al. Biomarker risk stratification with capsule sponge in the surveillance of Barrett’s oesophagus: Prospective evaluation of UK real-world implementation. Lancet; 23 Jun 2025; DOI: 10.1016/S0140-6736(25)01021-9
Image Credits: StillVision
Keywords: Esophageal cancer
Tags: alternatives to endoscopyBarrett’s oesophagus surveillancecapsule sponge testesophageal cancer preventiongastroesophageal reflux diseasehealthcare resource efficiencymetaplastic transformation in esophagusNHS healthcare challengesnon-invasive esophageal cancer monitoringpatient comfort in cancer diagnosisPill-on-a-Threadprecancerous cell changes